This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Secondly, and perhaps most importantly, Wall Street analysts -- at least those with a bullish view on the company -- think Anavex stock is massively undervalued right now. Anavex is a late-stage drugmaker with promising candidates in Alzheimer's disease, Parkinson's disease, Rett syndrome, and Schizophrenia, among others. Last December, blarcamesine reportedly hit the mark in a late-stage trial as an oral treatment for patients who have Alzheimer's disease.